Dubai World Challenge for Self-Driving Transport Winners Announced for Prizes Worth USD 5.1 Million
Dubai World Congress for Self-Driving Transport; organised by Roads and Transport Authority (RTA) Dubai on 15th and 16th October 2019 has attracted more than 700 technology leaders and innovators as well as 3000 visitors of the accompanying exhibition. The congress focuses on cutting-edge technologies, besides discussing and developing a general legislative structure for autonomous transport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015006107/en/
Winners of the Dubai World Self-Driving Transport Challenge (Photo: AETOSWire)
The event is part of RTA’s efforts in support of the strategy unleashed by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, to make 25% of all trips in Dubai smart and driverless by 2030. The congress attracted 80 international experts, including five keynote speakers, who will be taking part in 40 lectures and 39 technical workshops.
The congress is shaping into an all-inclusive global platform for self-driving transport that brings together top experts, policymakers, technology developers, researchers and academia. The event aims to highlight the leading role of Dubai Government in self-driving transport and accelerate the drive to achieve the targets of Dubai Autonomous Transportation Strategy through attracting experts and technologies of self-driving transport to Dubai. The event also aims to raise public awareness about the latest technologies and future trends of transportation as well as identifying the potential impacts on investments and different transport strategies.
Dubai Challenge
Dubai World Challenge for Self-Driving Transport, which carries prize money of US$5.1 million (about 19m Dirhams) attracted 65 entities from 20 countries, 15 of them qualified for the finals. The challenge focused on the first and last-mile challenge of mobility journeys.
Five leading companies, three start-ups and seven local and foreign universities qualified for the finals. Qualifying vehicles were subjected to different scenarios and tests on a dedicated track tailor-made for testing such vehicles at the Dubai Silicon Oasis.
Tests carried included stopping at bus stops, forced stop, overtaking a stopping vehicle, overtaking a bike, and dealing with various traffic scenarios such as signals, pedestrian crossing, road works, and sand on road. Tests also covered negotiating a roundabout, handling of humps, rains and high-speed turns.
Nominees for the challenge were qualified on certain parameters including the status, credibility, vision, skills and relevant experience of the entity. They were then subjected to several tests in various categories to assess their performance under six key standards and 18 subsidiary standards. Key standards covered the operation plan, tolerance and reliability, sustainability and energy, customer experience, safety and security, and dealing with road users.
Awards
The list of winners was delivered by autonomous delivery bot Roxo developed by FedEx Express in a fitting move with Dubai being selected as the first city outside the USA to host the test of this personal delivery bot. French companies swept the prizes of leading companies amounting to USD 3 million. Gaussin won the sustainability and energy award, Navya won the durability and reliability award as well as the customers' experience award.
In the start-ups category the first USD 1 million went to Sensible 4 from Finland, while the runner-up was iAuto from Taiwan who bagged USD 500,000 while UAE-based Derq Company finished third.
Amongst the international universities, the winner was Freie Universität Berlin which received USD 200,000; while Carlos III de Madrid University won second place with USD 100,000 and the Australian University UTS came third. In the local universities, Dubai University finished first with USD 200,000; UAE University came second bagging USD 100,000 and Al Ain University was third.
The Dubai World Challenge for Self-Driving Transport comprised several phases. In February 2018 the challenge was announced, and in October 2018 qualifiers for Phase II were announced. In February 2019, Phase II started and in March tests started at Dubai Silicon Oasis. From April to June this year, a team made overseas visits to Taiwan, Finland, Australia, Germany and Spain to assess start-ups and academia. In July qualifiers arrived in Dubai to collect geographical data about test tracks and draw maps, and in August vehicle tests started on the challenge track. Winners were selected according to results achieved in tests.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015006107/en/
Contact information
Roads and Transport Authority (RTA)
Maryam Al Balooshi, Manager, Media Communication
Marketing and Corporate Communication Department
Tel: +97142902699
Email Maryam.HAlblooshi@rta.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
